chemieunternehmen.com

Evotec AG today announced that its strategic alliance (TargetBCD) with Sanofi in the field of diabetes has reached an important milestone, triggering a payment of EUR 3.0 m to Evotec, for achieving pre-clinical proof-of-concept. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-achieves-first-milestone-in-diabetes-alliance-with-sanofi-5452

Evotec AG today announced that its partner Forge Therapeutics („Forge“) has received a research award from CARB-X (Combating Antibiotic Resistant Bacteria) of $ 8.8 m to advance its novel Gram-negative antibiotic programme targeting LpxC for the treatment of bacterial infections. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotecs-partner-forge-therapeutics-receives-prestigious-carb-x-research-award-5450

Evotec AG today announced its financial results and corporate updates for the fiscal year ended 31 December 2016. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-fiscal-year-results-2016-leading-innovation-efficiency–first-in-class-drug-discovery-5448

Evotec AG and Business France today released their short film about Evotec’s research site in Toulouse, France, under the headline: “Evotec found Business in France – Great story, short film”. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/great-story—short-film-5441

Evotec AG is pleased to announce that LAB282, the £ 13 m (over EUR 15 m) drug discovery partnership with Oxford University, has made its first wave of awards, backing projects targeting cardiovascular diseases and infectious diseases. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-ag-lab282-awarded-first-projects-5440

Evotec AG today announced that it resolved on a capital increase from its authorised capital against cash. Evotec will issue 13,146,019 new shares to Novo A/S (Denmark). Novo A/S is the independent holding company for the Novo Group. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/novo-as-becomes-new-long-term-strategic-shareholder-in-evotec-5630

Evotec AG today announced that Cyprotex, a company wholly owned by Evotec AG, has completed the relocation of its UK operations from Macclesfield to Alderley Park. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/cyprotex-an-evotec-company-expands-into-new-uk-facility-at-alderley-park-5434

Evotec AG today announced it has entered into an integrated drug discovery collaboration on an ion channel target with Asahi Kasei Pharma Corporation, a wholly owned subsidiary of Asahi Kasei Corporation, Tokyo, Japan. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-enters-into-an-integrated-drug-discovery-collaboration-with-asahi-kasei-pharma-japan-5432

Evotec AG and MaRS Innovation today announced the launch of Fibrocor Therapeutics LP („Fibrocor“), a Toronto-based company focused on developing first-in-class therapeutics targeting fibrotic diseases.  Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-and-mars-innovation-establish-strategic-partnership-to-launch-fibrocor-therapeutics-5430